Q4 2024 Azenta Inc Earnings Call Transcript
Key Points
- Azenta Inc (AZTA) delivered strong results in the quarter and year, with full-year revenue of $656 million, in line with guidance.
- The Sample Management Solutions and Multiomics segments grew core revenue by 4% for the year, excluding B Medical.
- The company announced the sale of B Medical, allowing a refocus on high-quality core businesses with opportunities for growth and margin expansion.
- Azenta Inc (AZTA) achieved an adjusted EBITDA margin of 10.2% in Q4, representing a significant margin expansion of over 550 basis points year-over-year.
- The company returned $249 million to shareholders through its share repurchase program, completing a $1.5 billion buyback over two years.
- Revenue was down 2% year-over-year on an organic basis, indicating challenges in the current market environment.
- B Medical revenue declined by 35% year-over-year, impacting overall financial performance.
- The company faces ongoing pricing pressure in the Multiomics segment, particularly in next-generation sequencing.
- Azenta Inc (AZTA) has identified complexity within its operations, stemming from 15 legacy acquisitions, which it aims to address through simplification initiatives.
- The guidance for fiscal 2025 indicates only 3% to 5% organic revenue growth, reflecting macroeconomic uncertainties and market challenges.
Greetings, and welcome to the Azenta fourth quarter 2024 financial results. (Operator Instructions) As a reminder, this conference is being recorded on Tuesday, November 12, 2024.
I will now turn the conference over to Yvonne Perron, Vice President, FP&A and Investor Relations.
Thank you, operator, and good afternoon to everyone on the line today. We would like to welcome you to our earnings conference call for the fourth quarter of fiscal year 2024. Our fourth quarter earnings press release was issued after the close of the market today and is available on our Investor Relations website located at investors.azenta.com in addition to the supplementary PowerPoint slides that will be used during the prepared remarks today.
I would like to remind everyone that during the course of the call, we will be making a number of forward-looking statements within the meaning of the Private Litigation Securities Act of 1995. There are many factors that
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
